Cost minimization analysis of treatments for metastatic HER2-positive breast cancer: Fixed-Dose combination of pertuzumab and trastuzumab for subcutaneous injections

Cost minimization for HER2-positive breast cancer

Miguel Figallo1*, María F. Delgado2, Mauricio Gonzalez1, Adrián Arenas3

1 APOYO Consultoría, Lima, Peru
2 London School of Economics, London, UK
3 Universidad de Piura, Lima, Perú

* Corresponding author
E-mail: mfigallo@apoyoconsultoria.com (MF)

https://orcid.org/0009-0008-1308-8677

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Abstract

The main objective of this study is to determine whether the employment of fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (or Phesgo) to treat metastatic HER2-positive breast cancer patients would minimize costs compared to the traditional treatment of separate intravenous doses of pertuzumab and trastuzumab in Peru. To achieve this, we used EsSalud (the social security health insurance) data and assessed it through a mixed strategy, which consisted of a quantitative and a qualitative approach. The first one aimed to calculate the direct (non-drug consumables, drugs, and healthcare professionals) and indirect costs of both treatments to develop a comparison, whilst the second aimed to validate information and internalize the procedure in an EsSalud context.

Overall, we found that the usage of Phesgo would be cost saving in EsSalud’s context. Specifically, we found three main insights. Firstly, the savings produced from switching from the traditional intravenous treatment to the subcutaneous one would allow EsSalud to afford full annual costs of 2 additional treatments, but without increasing their budget. This would cover 7% of the gap of 29 patients who do not have access to full treatment. Secondly, the result of a univariate sensitivity analysis in this work indicates that the price of Phesgo would have to increase by 16% so that both treatments cost the same. Thirdly, to increase the number of patients, the intravenous treatment would have to be totally replace by the Phesgo treatment, since the use of the latter requires less personnel and infrastructure.
Introduction

In Peru, breast cancer is the second most common neoplasm, affecting mainly women over 34 years of age. By 2022, 3,166 new cases of breast cancer were reported in Peru, 18% more than the previous year [1]. Within the subtypes of breast cancer, HER2-positive is a type of breast cancer whose cells have higher levels of the HER2 protein, which is present on the outside of all breast cells and promotes their growth [2]. According to the Peruvian Social Security (EsSalud), this type represents about 25% of all cases of breast cancer (EsSalud, 2017) and it is related with poor prognosis and aggressiveness.

The standard treatment applied by EsSalud for this type of neoplasm consists of the application of anti-HER2 medications —pertuzumab and trastuzumab— which are infused separately into a vein (IV). According to the in-depth interviews, a rough approximation of 30% of patients with HER2-positive metastatic breast cancer are not receiving the pertuzumab and trastuzumab treatment regime. This dual treatment scheme for patients with HER2-positive breast cancer in metastatic stage who have not received previous systemic therapy was approved by Essalud in 2017 [3].

Besides, the Peruvian Ministry of Health (Minsa) approved the treatment in March of 2023, but indicating that it is not cost-effective, and that its purchase should be given through what they call “differentiated mechanisms of acquisition”. The resolution argued that the incremental cost per year of life gained (YLG) in a patient using pertuzumab was above the cost-effectiveness threshold established by Minsa (16). Moreover, this decision relied on the results of the CLEOPATRA study, which was conducted between 2010 and 2018, and sought to analyze the efficacy of the addition of pertuzumab to the traditional treatment of docetaxel and trastuzumab for patients with metastatic HER2-positive breast cancer. The study showcased an improvement in progression-free and overall survival (OS), with a median of 57.1 months in the pertuzumab group and 40.8
months in the placebo group [4]. The difference in the overall survival is strongly
significant, as it has a p-value of 0.0008.

The IV administration has major disadvantages, mainly on the patient’s side, in terms of
the large number of hours they must spend at the healthcare facility, as well as the
considerable discomfort its application entails. Similarly, being a long treatment that
requires many supplies, it generates significant costs for the healthcare facility, both in
the price of consumables and in the time spent by healthcare professionals.

The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection
(PH FDC SC; and Phesgo as brand name) has come up as an alternative treatment
method for metastatic HER2-positive breast cancer. This treatment utilizes the same
drugs as in the standard of care —pertuzumab and trastuzumab—, however, they are
administered via a subcutaneous injection (SC), which adds an enzyme called
hyaluronidase.

The literature surrounding this topic has previously addressed the advantages of
employing the pertuzumab and trastuzumab combined treatment, additional to the cost
minimization due to transitioning from the IV to the SC treatment.

Regarding the advantages of Phesgo, works such as the FeDeriCa study, have shown
that this treatment has the same level of efficacy and offers key advantages when
compared to the IV treatment (IV) [5]. Additionally, the PHranceSCa study, showcases
that breast cancer patients prefer the subcutaneous treatment over the IV scheme [6].
That is because it reduces clinic time and enhances comfort during administration.

Hence, based on the literature, the following benefits are generated by the application of
Phesgo:

- **On the patient’s side**, it presents much shorter administration and observation
times, which has reduced the impact of undergoing cancer treatment on their
daily lives, as it increases the amount of time they can devote to productive
activities, leisure time, and family time, among others. Besides, the application of
SC treatment is considerably less intrusive and uncomfortable.

- **On the healthcare facility side**, it has been possible to release capacity in the
  chemotherapy units for other treatments, significantly reduce intravenous
  compounding costs, and reduce wastage. On the other hand, it saves costs for
  the healthcare provider, using less active employee time and reducing non-drug
  consumable costs.

Now, with regards to the cost minimization of transitioning to the SC treatment, we
identified three key studies that have shed light on the topic at hand. Firstly, one
approached the cost minimization through the reduction of non-drug costs and other
related economic costs such as HCP (Health Care Professional) time and patient time
[7]. Secondly, other used a Time and motion (T&M) methodology to also estimate the
time cost of both the IV and SC treatments, and the direct and indirect costs associated
with these [8]. It concluded that a transition to SC in a Spanish context would significantly
reduce direct costs in 979.60 euro per full cycle treatment as well as reduce the time
used, which minimized the loss of productivity. Thirdly, in a similar study conducted in
Cuba, it was found that the subcutaneous treatment proved to minimize costs with
respect to the intravenous treatment even when its price was increased by 30% [9]. This
result differs from what will be shown afterwards because the characteristics of both
healthcare systems have critical differences.

On the one hand, the prices of the IV and SC anti-Her2 drugs are considerably higher
than what we are considering. In fact, almost all the savings that study found were
explained by that source. On the other hand, the non-drug consumables that are
considered in the Cuban study are considerably cheaper than what is considered in this
study, which discards non-drug consumables as a relevant source of savings. Finally,
the Cuban estimation for IV procedures duration is higher than ours, which explains why
their time savings are higher than ours.

As it has been shown, Phesgo appears to have similar efficacy and safety profile when
compared to the IV scheme, making it reasonable to determine whether it minimizes the
treatment costs in EsSalud and in which magnitude. Hence, this study aims to identify
savings opportunities for both patients and healthcare facilities, so that the public
expenses execution is optimized without deterring the quality of attention. This is
particularly important in the context of high limitations and deficiencies present in the
Peruvian healthcare system.

Materials and methods

Data used

We use public information from the Peruvian social health security. We use the following
sources of data:

Hospital administrative documents: We retrieved the annual salaries of nurses and
pharmaceutical chemists and accessed the list of EsSalud strategic purchases [10]. The
latter list included the prices and specific characteristics (size, type, etc.) of drugs, non-
drug consumables, and medical equipment for cancer treatment. Finally, the pertuzumab
and trastuzumab monthly consumption series and the number of chemotherapy couches
were provided by EsSalud. The latter pieces of information were at the hospital level and
allowed us to estimate both the number of treated patients and the nationwide attention
capacity.

Clinical practice guidelines: The HER2-positive metastatic and non-metastatic breast
cancer clinical practice guidelines contain the step-by-step process and medication
needed for the IV treatment [11]. This information served as an input for the in-depth
interviews that were followingly conducted.
Methodology

The study followed a mixed strategy, which considered both a quantitative and qualitative approach. Under the quantitative approach, following recent contributions, we considered a time horizon of a full year and a singular patient approach. Given that the treatment is applied every 21 days, we estimate the cost of a total of 18 cycles or doses per year, which is consistent with previous contributions [9] [7] [8]. Accordingly, for that period of treatment, we defined 3 different stages for HER2-positive metastatic breast cancer:

i. **Loading (1 cycle):** It refers to the initial cycle of each treatment, the following cycles are known as maintenance. Chemotherapy is applied in this cycle along with trastuzumab and pertuzumab by IV infusion separately or both together by Phesgo injection subcutaneously.

ii. **Maintenance with chemotherapy (5 cycles):** For the first 5 maintenance cycles, chemotherapy must be applied, along with pertuzumab and trastuzumab.

iii. **Maintenance with no chemotherapy (12 cycles):** For the rest of the 12 maintenance cycles, the treatment is with trastuzumab and pertuzumab. No chemotherapy is required.

For the calculation of costs, we considered the direct and indirect costs. For direct costs, the following three categories were included: (i) non-drug consumables, (ii) drugs, and (iii) healthcare professionals. In the case of indirect costs, we considered an estimation of the value of time of patients to get the savings or losses attributable to the change in the treatment scheme. This calculation used as an input the statistic value of life [12]. Further methodological details of this estimation are provided in Section 5.

On the qualitative side, two in-depth interviews with key EsSalud personnel were carried out. The first one covered the treatment room procedures whilst the second one provided
a closer approximation to the oncology mixing room procedures, both executed
simultaneously. Both interviews validated information such as: (i) the duration of each
identified procedure, and (ii) the specific inputs needed for the execution of each
procedure. Those pieces of information were provided as ranks, which let us internalize
the variability that time and quantities can suffer when administrating the treatment in the
EsSalud context.

Treatment schemes characterization

The most widely used targeted anti-HER2 treatment is intravenous pertuzumab and
trastuzumab (IV). In the case of the Peruvian health system, chemotherapy sessions are
applied throughout the treatment cycle [13]. Based on local clinical guidelines and on
relevant literature, validated through the interviews with the healthcare professionals, an
orderly structure of the steps of the IV treatment for HER2-positive metastatic breast
cancer applied by EsSalud was constructed. In addition, the structure for SC treatment
was recovered based on the literature reviewed. They are both illustrated below in Fig 1.

Fig 1. Stages in IV and SC treatment schemes. Note: Mixing room preparation
procedures occur simultaneously with the previous ones (cannulation, hydration,
premedication).

Results

Cost minimization

We obtained all the costs involved in the treatment of breast cancer, both for the
healthcare facility and for the patient, to make an exhaustive comparison between the
total costs that each treatment scheme entails. In that sense, the costs of a year of
treatment in terms of drug and non-drug consumables, lost staff capacity and patient
hours are also calculated. This section compares the total annual costs of IV and SC
treatments and highlights the savings that the SC scheme represents over IV for the
following categories: (i) non-drug consumables, (ii) healthcare professionals, (iii) indirect costs, and (iv) drug costs.

From previous contributions [7], one can find that the non-drug saving in the United States is of 75%, which is mainly driven by chair time costs (62% of total savings, which equals 75% in this study). For our case, in Fig 2, the total annual costs per patient for each category, excluding drug costs, are shown for both the IV and SC schemes, and the estimated difference between the two is calculated. It is shown that the total annual savings per patient is US$ 5,395, which represents a reduction of approximately 64% of the cost of the IV scheme without including drug costs.

It is worth stressing, however, that this estimation does not represent the overall saving of Phesgo, nor does it represent how much can the price of Phesgo be increased while still minimizing costs. The correct interpretation to this estimation contemplates that this is the savings in non-drug costs.

**Fig 2. Annual cost per patient without drug costs, IV vs SC (US$).**

Followingly, in Table 1 a breakdown of each category including drug costs is made to analyze in detail the total savings per patient for each of them and which are the main sources —materials or procedures— through which these savings are perceived. A purchase period for nun-drug consumables and drugs is considered between September 5 and 7, 2022.

### Table 1. Annual savings per category (US$)

<table>
<thead>
<tr>
<th>Category</th>
<th>Savings per patient</th>
<th>Main sources of savings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct costs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 Healthcare professionals</td>
<td>US$ 1314</td>
<td>• Preparation in mixing room (US$ 394)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Administration of monoclonal antibodies (US$ 272)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Hydration (US$ 227)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Monitoring after monoclonal antibodies (US$ 201)</td>
</tr>
<tr>
<td>Category</td>
<td>Cost</td>
<td>Items</td>
</tr>
<tr>
<td>------------------------</td>
<td>--------------</td>
<td>--------------------------------------------</td>
</tr>
<tr>
<td>Non-drug consumables</td>
<td>US$ 999</td>
<td>• Short double-lumen catheter (US$ 812)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Venoclysis equipment (US$ 91)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Trifurcated equipment (US$ 68)</td>
</tr>
<tr>
<td>Drug costs</td>
<td>US$ 332</td>
<td>• Monoclonal antibodies (US$ 306)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Sodium chloride 250 cc (US$ 15)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Sodium chloride 1 L (US$ 7)</td>
</tr>
<tr>
<td>Indirect costs</td>
<td>US$ 3,082</td>
<td>• Administration of monoclonal antibodies</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(US$ 911)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Hydration (US$ 762)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Monitoring after monoclonal antibodies</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(US$ 673)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Vein cleaning (US$ 355)</td>
</tr>
</tbody>
</table>

**Note:** This list is not exhaustive. It only considers the main sources of savings. Hence, the sum of the sources of savings will not necessarily equal the savings per patient shown.

**Indirect costs**

For the estimation of indirect costs, we considered the patients’ loss of productivity generated by the time in clinic (waiting and treatment time). To reach that estimation, we calculated both the time in clinic and the value of patients’ time. The following steps were followed:

- **For estimating the time in clinic:** Based on the clinical practice guidelines and the in-depth interviews, we calculated the total time spent in clinic by each patient in each treatment cycle.
- **For the value of patients’ time:** We took advantage of the statistic value of life [12] which provides a vector of statistic values for each year of life going from 0 to 99. These calculations were based on the human capital method, which means that the values of life that he provided represent the total productivity of a representative individual at each year of age.
By taking advantage of the number of ambulatory attentions related to breast cancer available at the REUNIS database, we obtained weights for estimating an average statistic value of life adjusted to the representative breast cancer patient. After obtaining this weighted average, we were able to monetize the time saved as a consequence of the use of Phesgo, which yielded a total saving per patient of US$3,082. This saving represents a reduction of 63% when compared to the IV scheme.

The main savings are perceived in the stages of: (i) administration of monoclonal antibodies, (ii) hydration, (iii) monitoring after monoclonal antibodies and (iv) vein cleansing, which account for 88% of the total savings in this category. The reasons behind the savings are the same as for the healthcare professional's category; however, in this case, the preparation in mixing room does not come into play since this stage does not require patient time.

Healthcare professionals

Regarding the time saved by the healthcare professionals, the time spent in each procedure of both treatments was collected from the interviews and clinical guidelines. Based on those inputs, the nurse-minute costs were calculated (US$ 0.25). As a result, a total saving of $1,314 in healthcare professionals’ costs was estimated. This represents a reduction of 66% with respect to the IV scheme.

The main savings come from the stages of preparation in the mixing room, followed by administration of monoclonal antibodies, hydration and monitoring after monoclonal antibodies. These savings collectively represent 83% of the total savings in this category. Since in the SC treatment there are several procedures that are not applied after the first 6 cycles, as can be seen in Fig 1. In addition, other procedures require nurses to dedicate less time to the treatment, such as the administration and monitoring of pertuzumab and trastuzumab.
Table 2 shows the savings in terms of hours of healthcare professionals in the SC scheme compared to the IV scheme.

**Table 2. Hours spent by healthcare professionals for the treatment of a single patient, by stage per year.**

<table>
<thead>
<tr>
<th>Stage of treatment</th>
<th>IV</th>
<th>SC</th>
<th>Savings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Loading (1 cycle)</td>
<td>7.5</td>
<td>4.6</td>
<td>39%</td>
</tr>
<tr>
<td>Maintenance with chemotherapy (5 cycles)</td>
<td>30</td>
<td>21.5</td>
<td>28%</td>
</tr>
<tr>
<td>Maintenance with no chemotherapy (12 cycles)</td>
<td>60</td>
<td>10</td>
<td>83%</td>
</tr>
<tr>
<td><strong>Total hours spent per year</strong></td>
<td>97.5</td>
<td>36.1</td>
<td>63%</td>
</tr>
</tbody>
</table>

**Note:** For both treatment schemes, a constant initial evaluation period of 30 minutes per cycle is considered in the total hours spent.

Although these savings do not directly reduce the budget, they represent a release of human resources capacity for the attention of other patients. Furthermore, this will alleviate the overburden and distress that the healthcare personnel currently go through, which will in turn improve the overall quality of the service. The benefits of this attention capacity release are addressed afterwards.

**Non-drug consumables**

Regarding the non-drug consumables, the main inputs for the analysis were: (i) prices, which were obtained from the EsSalud’s catalogs; (ii) quantities required for each treatment scheme, which were collected from clinical guidelines and interviews. As a result of the analysis, a total saving of US$999 in non-drug consumables per patient was estimated. This represents a reduction of 62% with respect to the IV scheme.

The main saving comes from the reduction in the use of: (i) short double-lumen catheter, (ii) venoclysis equipment, and (iii) trifurcated equipment. The savings generated by the disuse of these three elements represent 97% of the total saving in this category, this is because in the SC treatment these instruments are used only in the first 6 cycles when chemotherapy is applied, while in the IV treatment they are used in all cycles. Minor
savings are also perceived because in the IV treatment additional consumables are used in the mixing room for the preparation of pertuzumab and trastuzumab, which do not apply to the SC treatment.

A table is presented showing the annual costs in non-drug consumables represented by the inputs of the IV and SC treatment schemes. In that table, considerable savings can be observed in the SC scheme with respect to the IV scheme (Table 3).

As Table 3 shows, the savings are not uniformly distributed across the defined stages. This is so because, in the SC treatment scheme, the catheter is only used in the first 6 cycles when chemotherapy is applied, whilst in the IV scheme, it is used throughout the entire treatment. In addition, since several stages of the SC scheme are only applied in the chemotherapy cycles, as shown in Fig 1, the healthcare facility experiences significant savings in terms of non-drug consumables.
Table 3. Annual costs and savings from non-drug consumables (US$)

| (i) Non-drug consumables | Unit cost | First 6 cycles | | Last 12 cycles | | Total | | Total |
|--------------------------|-----------|----------------|------------|----------------|------------|-------|-------|
|                          |           | IV  | SC  | IV-SC | IV  | SC  | IV-SC |          |          |
| Short double lumen catheter 2 FR | 97         | 406 | 406 | -     | 812 | -   | 812   | 812      | 67%       |
| Venoclysis equipment     | 8         | 45  | 45  | -     | 91  | -   | 91    | 91       | 67%       |
| Trifurcated equipment    | 6         | 34  | 34  | -     | 68  | -   | 68    | 68       | 67%       |
| PORT catheter needle     | 5         | 9   | 9   | -     | 17  | -   | 17    | 17       | 67%       |
| 20 cc syringe            | 0         | 2   | 1   | 1     | 3   | -   | 3     | 4        | 86%       |
| Tegaderm 6x7             | 0         | 2   | 2   | -     | 4   | -   | 4     | 4        | 67%       |
| 18 X 1 1/2" needle      | 0         | 1   | 0   | 0     | 1   | -   | 1     | 2        | 79%       |
| 10 cc syringe            | 0         | 1   | 1   | 1     | 1   | -   | 1     | 1        | 67%       |
| 5 cc syringe             | 0         | 0   | 1   | 0     | 1   | -   | 1     | 1        | 50%       |
| 20 X 1 1/2" needle      | 0         | 0   | 0   | 0     | -   | -   | -     | 0 (233%) |          |
| 22 X 1 1/2" needle      | 0         | 0   | 0   | 0     | 0   | -   | 0     | 0        | 67%       |
| PORT catheter            | 287       | 86  | 86  | -     | -   | -   | -     | -        |          |
| Infusion line            | 5         | 32  | 32  | -     | -   | -   | -     | -        |          |
| Package of gauze         | 0         | 0   | 0   | 0     | 1   | -   | 1     | -        |          |
| **Total**                | **408**   | **618** | **617** | **1** | **999** | **1** | **998** | **999** | **100%** |

Note: All numbers are rounded to the nearest integer. Prices were retrieved from EsSalud strategic purchases catalog. We use the average exchange rate for the month of December 2022 reported by the Central Reserve Bank of Peru. (PEN/US$: 3.829).
Drug costs

The use of Phesgo in this treatment also reduces drug costs. This includes the costs and quantity of medicines used in both treatment schemes: pertuzumab, trastuzumab, docetaxel, sodium chloride, and ondansetron, among others. Even under the assumption that Phesgo price is equivalent to the sum of prices available of pertuzumab and biosimilar trastuzumab, there is a reduction of US$ 332. This represents a saving of less than 1% on drug costs. In Table 4 the price of the main drugs applied in treatments is shown.

Table 4. Price of main drugs (US$)

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pertuzumab 420 mg/14 mL</td>
<td>1,941</td>
</tr>
<tr>
<td>Trastuzumab 21 mg/mL x 20 mL (with diluent)</td>
<td>186</td>
</tr>
<tr>
<td>Phesgo – Loading (1200 mg of Pertuzumab)</td>
<td>3,192</td>
</tr>
<tr>
<td>Phesgo – Maintenance (600 mg of Pertuzumab)</td>
<td>2,128</td>
</tr>
</tbody>
</table>

Table 5 showcases that the main savings come from the application of monoclonal antibodies. On one hand, particularly, from the extra trastuzumab and pertuzumab that is required by the IV scheme when reconstituting the drugs. It is worth mentioning that the trastuzumab vial purchased by EsSalud is standardized and contains 21 mg/ml x 20 ml. Since the trastuzumab dose depends on the weight of the patient, more or less than one vial may be required. This parameter was estimated considering a women average weight of 57 kg [14]. Specifically, for the loading cycle, 8mg/kg are applied; for the maintenance cycles, 6 mg/kg are applied. Having a standardized vial of 420 mg and considering the average weight, 456 mg (1.09 vials) would be necessary for the loading cycle, whilst 342 mg (0.81 vials) would be necessary for maintenance cycles.

On the other hand, Phesgo provides a fixed dose, and its price is equal to the sum of the prices of pertuzumab and trastuzumab, except for the loading cycle, where the price of
Phesgo is multiplied by a factor of 1.5 (this is consistent with its current global pricing strategy). Hence, spending on a fixed dose of SC results cheaper than spending on the alternative, which may require additional expenditures on trastuzumab depending on the patient’s weight. As it is not plausible to expect a uniform distribution for patients’ weight, there is a variable leftover of trastuzumab in the IV scheme. Our model considers an ideal case in which this leftover is never wasted. However, this assumption stresses the results because it reduces the drug costs of the IV scheme, which underestimates the savings generated by the adoption of Phesgo. For every 1% of leftover wasted, savings increase in US$ 26, which represents 8% of the estimated drug costs savings. Under the extreme case in which the whole leftover is wasted, savings in drug costs would equal US$ 589.

However, the above-mentioned savings are concentrated in the first 6 cycles of treatment, and, particularly in the loading cycle. Considering an average-weight patient, the first cycle of the IV scheme requires the use of two vials of pertuzumab, which would cost US$ 3,882, and 456 mg of trastuzumab which would cost US$ 203. Thus, the application of monoclonal antibodies under the IV scheme requires an expenditure of US$ 4,085 only for the loading cycle. In comparison, the SC scheme takes advantage of a fixed loading dose of Phesgo, which costs US$ 3,192, which implies a saving of US$ 893 only for the first cycle.

The following cycles (2-18) showcase minor de-savings, which are visible in the first row of Table 5. The reason behind those losses is the assumption of no waste of leftovers. As it is detailed in footnote 10, the use of this assumption underestimates the pharmacological savings of Phesgo because it considers an ideal setting in which the content of each vial of trastuzumab is perfectly distributed and consumed. Notwithstanding the above, the pharmacological savings resist this extreme scenario, which strengthens the savings capacity of Phesgo. Fig 3 shows a breakdown of all savings and de-savings received in all 18 cycles in one year divided by stage.
Fig 3. Savings and de-savings for all 18 cycles in drug costs of using Phesgo (US$).
### Table 5. Annual costs and savings from drugs (US$)

<table>
<thead>
<tr>
<th>(i) Drug consumables</th>
<th>Unit cost</th>
<th>First 6 cycles</th>
<th>Last 12 cycles</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>IV</td>
<td>SC¹</td>
<td>IV-SC</td>
</tr>
<tr>
<td>Dual anti Her2 drugs</td>
<td>2,128</td>
<td>14,552</td>
<td>13,830</td>
<td>722</td>
</tr>
<tr>
<td>Sodium chloride 250cc</td>
<td>0</td>
<td>8</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>Sodium chloride 1L</td>
<td>1</td>
<td>4</td>
<td>4</td>
<td>-</td>
</tr>
<tr>
<td>Ondansetron 8 mg</td>
<td>0</td>
<td>2</td>
<td>2</td>
<td>-</td>
</tr>
<tr>
<td>Dexamethasone 2 mg</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>/ ml X 2 ml</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clorphenamine 10 mg</td>
<td>16</td>
<td>16</td>
<td>98</td>
<td>98</td>
</tr>
<tr>
<td>/ ml X 1 ml</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ranitidine 25 mg / ml</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>X 2 ml</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>2,145</strong></td>
<td><strong>14,665</strong></td>
<td><strong>13,938</strong></td>
<td><strong>727</strong></td>
</tr>
</tbody>
</table>

**Note:** All numbers are rounded to the nearest integer. Prices were retrieved from EsSalud strategic purchases catalog. We use the average exchange rate for the month of December 2022 reported by the Central Reserve Bank of Peru. (PEN/US$: 3.829). ¹/ The SC treatment is referred to Phesgo, while the IV treatment refers to the intravenous administration of pertuzumab and trastuzumab.
Payer’s costs

Two steps were followed to estimate the budgetary impact for the payer: (i) estimation of the number of patients treated with complete and incomplete treatment and (ii) monetary and non-monetary savings estimation, which we proceed to detail below.

Estimated number of patients

The number of patients was estimated through two different approaches. The first approach \textit{(top-down)} consisted of taking the total cases presented by GLOBOCAN 2020 of breast cancer in Peru (22,486) and disaggregating them progressively by multiplying it by the following probabilities: (i) suffering HER2-positive breast cancer (25-30%), (ii) suffering metastatic breast cancer (9%) reported by FISSAL, and (iii) being treated by EsSalud (18%, estimated by considering the total breast cancer patients attended by Minsa, EsSalud, and INEN). Fig 4 shows each step and intermediate result of this estimation. As it is shown, we concluded that EsSalud currently treats 100 HER2-positive patients in the metastatic stage.

Additionally, based on the in-depth interviews with key EsSalud personnel, an approximate of 30% of HER2-positive metastatic breast cancer are not treated with pertuzumab, despite requiring it. By considering this proportion of patients who do not have access to full treatment, we calculate that there is a gap of 30 patients who are not receiving proper treatment.

Fig 4. Top-down approach.

The second approach \textit{(bottom-up)} consisted of obtaining the expected monthly consumption of pertuzumab for a single patient. For that to happen, we used the probability of being a new patient (31%) by obtaining the 5-year prevalence of breast cancer (22,486) and the number of new cases per year (6,860). This probability allowed us to calculate an expected monthly consumption of 1.31 vials, considering that the
patient receives each dose once every month (although medical indication states that the dose must be applied every 21 days, we considered the considerable lags in administration). Therefore, this calculation was the result of the weighted sum of 1 vial consumed by a maintenance patient and 2 vials consumed by a new patient. Rescaling this value to an annual time frame yields an expected consumption of 15.66 per patient. Then, the total pertuzumab consumption of each healthcare facility was divided by the expected consumption per patient to get an estimate of the number of patients, which we calculate at 65.

Nonetheless, as this calculation took the consumption of pertuzumab as an input, we rescaled it to get the full universe of HER2-positive metastatic breast cancer. Specifically, we followed the fact that there is a gap of 30% who do not receive full treatment, which means that this 30% only receive trastuzumab.

This exercise allowed us to estimate that there was a full universe of 93 patients treated with either complete or incomplete treatment schemes, which yields a gap of 28 patients that do not have access to full treatment. Fig 5 shows each step and intermediate result of the described approach.

**Fig 5. Bottom-up approach.** Notes: 1/ Total number of vials of pertuzumab consumed in EsSalud during 2022. Recovered from the list of purchases of strategic goods. 2/ The estimation of the gap follows the fact that the number of patients with complete treatment are the 70% of the full universe of attended patients. Source: In-depth interviews.

Based on the above-described methodologies, it is estimated that the average gap of patients who do not access to full treatment is of 29, which, according to the information recovered in the interviews, can be explained by the restrictions and resource limitations that challenge the healthcare system. Table 6 shows the estimation, under each approach, of: (i) total attended patients, (ii) patients who access to full treatment.
(pertuzumab + trastuzumab), and (iii) gap of patients who do not have access to full treatment. In addition, it showcases the average estimates.

Table 6. Summary table - Number of patients estimation

<table>
<thead>
<tr>
<th>Approach</th>
<th>Attended patients</th>
<th>Full treatment</th>
<th>Access gap</th>
</tr>
</thead>
<tbody>
<tr>
<td>Top-down</td>
<td>100</td>
<td>70</td>
<td>30</td>
</tr>
<tr>
<td>Bottom-up</td>
<td>93</td>
<td>65</td>
<td>28</td>
</tr>
<tr>
<td><strong>Average</strong></td>
<td><strong>97</strong></td>
<td><strong>68</strong></td>
<td><strong>29</strong></td>
</tr>
</tbody>
</table>

Monetary and non-monetary savings for EsSalud

Based on the above estimates, the total EsSalud monetary savings in direct costs at the national level are US$ 90,535. This estimation considers both approaches’ average estimate of patients who currently access full treatment in EsSalud (68), it is calculated that the social security would save US$ 67,947 in non-drug consumables per year by adopting Phesgo. This represents 62% of what the social security system spends each year on consumables needed for the treatment of HER2-positive metastatic breast cancer. Additionally, the use of Phesgo generates savings in drug costs, as the SC treatment demands lower uses of premedication, hydration, and reconstitution. These savings are of US$ 22,588 per year. Moreover, a sensitivity analysis was performed, which showcased that an increase of 0.84% in the price of Phesgo is required for the savings in drug costs to be zero, and an increase of 3.38% is required for the savings in direct costs—which includes drug costs and non-drug consumables costs—to be zero.

Moreover, the adoption of the subcutaneous treatment would also have non-monetary savings in terms of (i) the availability of nurses and (ii) the release of chemotherapy chairs use time. Since the adoption of Phesgo generates an annual saving of 61 hours per patient and we estimate 68 currently attended patients, it is calculated that there will be a release of more than 4,000 nursing hours and chemotherapy chairs use time. As we estimate that 97 hours are required to attend a patient through a whole year under an IV scheme, we calculate that the freeing up of capacity would allow the attention of
41 additional IV patients per year without incurring on more investment costs than the needed to be able to close the access gap of 29 HER2-positive metastatic breast cancer patients, as specified in Table 6.

**Robustness checks**

To stress our results, several robustness checks were performed. In particular, we ran sensitivity analyses for two key variables: (i) price of Phesgo and (ii) price of Pertuzumab. Regarding the first test, Fig 6 provides three different scenarios that allow us to tell how total savings for a single patient are affected by the price of the SC treatment. Those scenarios are: (i) baseline, (ii) 5% increase in the price of Phesgo, and (iii) 5% decrease in the price of Phesgo without adjusting the price of pertuzumab and trastuzumab. Table 7 rescales the resulting savings for the payer (EsSalud) under each provided scenario.

A 5% increase in the price of Phesgo would reduce total savings in 34%, going from US$ 5,727 to US$ 3,759 per patient. This result features a de-savings of US$ 1,636 per patient in drug costs, which runs up to US$ 111,246 when rescaling it to the full universe of attended patients. However, what is more important is that, despite bearing this loss, total savings are positive. That is because we are not only considering direct savings for the payer—which are, in this case, negative and detailed in Table 7—, but savings in healthcare professionals and patients time, whose monetary equivalents are featured in Fig 6.

Besides, we find an expansion of savings when considering a 5% decrease in the price of Phesgo. Annual savings in drug costs go up to US$ 2,300 per patient, which is equivalent to a total saving of US$ 156,421 when rescaling it to the full social security system. This would have two strong benefits: (i) from a social perspective, savings experiment an increase of 34%, and (ii) from a payer’s perspective, savings experiment an increase of 148%.
Fig 6. Price of Phesgo sensitivity analysis for the annual savings of a single patient (US$). Note: For the construction of each scenario, every other variable is kept constant. The savings here portrait both the experimented by patients and the payer in a timeframe of a full year.

Table 7. Price of Phesgo sensitivity analysis for the annual savings of EsSalud (US$)

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>+5%</th>
<th>-5%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-drug consumables</td>
<td>67,947</td>
<td>67,947</td>
<td>67,947</td>
</tr>
<tr>
<td>Drugs</td>
<td>22,588</td>
<td>(111,246)</td>
<td>156,421</td>
</tr>
<tr>
<td>Monetary savings for the payer</td>
<td>90,534</td>
<td>(43,299)</td>
<td>224,368</td>
</tr>
</tbody>
</table>

Note: The savings here portrait consider a universe of 68 patients in the social security healthcare system (EsSalud). This number of patients follows Section 6, so it represents the estimated number of HER2-positive metastatic breast cancer treated with pertuzumab and trastuzumab.

As to the sensitivity analysis with respect to the price of pertuzumab, Fig 7 shows three different tests that were conducted. Each of these tests consisted in the progressive addition of savings boxes with the aim of finding the reduction in the price of pertuzumab that offsets the savings derived from the application of Phesgo. In particular, the first test considers up to box 1, which includes only the monetary savings for the payer. That is, the savings in drugs and non-drug consumables, which are equal to US$ 90,534. We find that a 3.6% decrease in the price of pertuzumab is sufficient to equal these savings.

The second test considers up to box 2, which adds patients’ savings in indirect costs. It is worth it to recall that these savings only considered measurable benefits that were monetizable, which are savings in productivity. These savings were calculated in US$ 209,556. In that sense, the second test consisted in finding a price of pertuzumab that let us offset the US$ 300,090 savings that are generated by boxes 1 and 2. We find that, for that to happen, there must be a 11.9% decrease in the price of pertuzumab.

Finally, we add a referential test –test 3– to stress the fact that there is a third box of savings that no reduction in the price of pertuzumab could offset. This group of savings contemplates non-monetary benefits both for patients and the payer. Regarding the
patients, there are important benefits such as: gain in comfort, gain in time for no productive activities, gain in overall utility. On the other hand, for the payer, there are other such benefits like: attention capacity increase, relief of overburden for nurses, among others.

**Fig 7. Pertuzumab price sensitivity analysis.** Note: The baseline price for pertuzumab is US$ 1,941. There is no estimation for test 3, as it contemplates a box of non-monetary savings.

**Conclusions and discussion**

As it was shown, switching from an IV to a SC treatment scheme produces significant monetary and non-monetary savings for the healthcare system and the patient. Despite this result, we estimate that the generated monetary savings allow EsSalud to afford the full annual costs of only 2 additional treatments without increasing its budget. This would cover 7% of the gap of 29 patients who do not have access to full treatment without increasing the budget. Moreover, by means of a univariate sensitivity analysis, it is obtained that the price of Phesgo would have to increase by 15.83% so that the costs of the two treatments are equalized and zero savings are perceived.

Furthermore, increasing the number of treated patients is only possible through the adoption of Phesgo instead of the current IV treatment. This is mainly because the use of Phesgo decreases the amount of infrastructure and personnel required to treat each patient. Otherwise, EsSalud would be required to invest in expanding the existing infrastructure to be able of closing the treatment gap, due to the constraints of healthcare resources. Therefore, even if biosimilars were to match the monetary savings of Phesgo (drug and consumables costs) and monetary savings were achieved, there would be no capacity to expand the current care.
Additional extensions to this study may cover a deeper qualitative approach, such as the collection of patients’ perceptions on which treatment increase their welfare. In the same way, we recommend future contributions to carry out the stopwatch measurement of the mixing and treatment room procedures, and the inclusion of further welfare components in the indirect costs, which we delimit to the loss of productivity. Finally, it would be relevant to test if the above conclusions are extensible to other Peruvian healthcare providers, such as the ones administered by the Ministry of health (Minsa).

Acknowledgments

We thank Rodrigo Castro for his help format this research paper for publication. His contribution ensured the professional presentation of this work.

Author Contributions

Conceptualization: Miguel Figallo, María F. Delgado, Mauricio Gonzalez.

Methodology: Miguel Figallo, María F. Delgado

Validation: Miguel Figallo, María F. Delgado, Mauricio Gonzalez

Formal analysis: María F. Delgado, Mauricio Gonzalez, Adrián Arenas

Data Curation: Miguel Figallo, María F. Delgado, Mauricio Gonzalez, Adrián Arenas.

Writing - Original Draft: Miguel Figallo, María F. Delgado, Mauricio Gonzalez.

Writing - Review & Editing: Miguel Figallo, Mauricio Gonzalez, Adrián Arenas.

Visualization: Miguel Figallo, Mauricio Gonzalez.

Supervision: Miguel Figallo.

Project administration: Miguel Figallo.
Funding acquisition: Miguel Figallo.

References


 CC-BY 4.0 International license
 It is made available under a CC-BY 4.0 International license.
<table>
<thead>
<tr>
<th>Intravenous treatment</th>
<th>Subcutaneous treatment during chemotherapy cycles (first 6 cycles)</th>
<th>Subcutaneous treatment without chemotherapy cycles (last 12 cycles)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evaluation and installation</td>
<td>Evaluation and installation</td>
<td>Evaluation and installation</td>
</tr>
<tr>
<td>Intravenous cannulation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydration and premedication</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mixing room preparation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pertuzumab administration</td>
<td>Phesgo SC administration</td>
<td>Phesgo SC administration</td>
</tr>
<tr>
<td>Post pertuzumab monitoring</td>
<td>Post Phesgo SC monitoring</td>
<td>Post Phesgo SC monitoring</td>
</tr>
<tr>
<td>Trastuzumab administration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post trastuzumab monitoring</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Docetaxel administration</td>
<td>Docetaxel administration</td>
<td></td>
</tr>
<tr>
<td>Vein cleaning and disconnection of the track</td>
<td>Vein cleaning and disconnection of the track</td>
<td>The application of Phesgo presents savings in terms of time and input usage.</td>
</tr>
</tbody>
</table>

**Figure 1**
Figure 2
Figure 4

Total cases of breast cancer in Peru: 28%

HER2-positive breast cancer cases: 9%

Metastatic breast cancer cases: 18%

Affiliates of EsSalud: 30%

HER2-positive metastatic breast cancer cases treated by EsSalud

HER2-positive metastatic breast cancer patients who do not have access to full treatment
Figure 7

- Non monetary benefits for the payer and patients